Price Alert

Emergent BioSolutions Inc... (EBS)

NYSE: EBS · Real-Time Price · USD

7.59

-0.04 (-0.52%)

At close: Sep 05, 2025, 3:59 PM

7.61

0.26%

After-hours: Sep 05, 2025, 07:27 PM EDT

Emergent BioSolutions Statistics

Share Statistics

Emergent BioSolutions has 53.35M shares outstanding. The number of shares has increased by 0.48% in one year.

Shares Outstanding	53.35M
Shares Change (YoY)	0.48%
Shares Change (QoQ)	-0.11%
Owned by Institutions (%)	66.53%
Shares Floating	51.05M
Failed to Deliver (FTD) Shares	4,901
FTD / Avg. Volume	0.38%

Short Selling Information

The latest short interest is 9.82M, so 18.08% of the outstanding shares have been sold short.

Short Interest	9.82M
Short % of Shares Out	18.08%
Short % of Float	18.27%
Short Ratio (days to cover)	5.62

Valuation Ratios

The PE ratio is -2.66 and the forward PE ratio is 7.94. Emergent BioSolutions's PEG ratio is 0.04.

PE Ratio	-2.66
Forward PE	7.94
PS Ratio	0.5
Forward PS	0.4
PB Ratio	1.05
P/FCF Ratio	14.15
PEG Ratio	0.04

Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Emergent BioSolutions.

EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 3.69, with a Debt / Equity ratio of 1.37.

Current Ratio	3.69
Quick Ratio	1.77
Debt / Equity	1.37
Debt / EBITDA	17.99
Debt / FCF	18.54
Interest Coverage	-1.53

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity	n/a
Return on Assets	n/a
Return on Invested Capital	n/a
Revenue Per Employee	$1.13M
Profits Per Employee	$-211.78K
Employee Count	900
Asset Turnover	0.73
Inventory Turnover	n/a

Taxes

Income Tax	47.7M
Effective Tax Rate	-33.38%

Stock Price Statistics

The stock price has increased by 0.93% in the last 52 weeks. The beta is 2.04, so Emergent BioSolutions's price volatility has been higher than the market average.

Beta	2.04
52-Week Price Change	0.93%
50-Day Moving Average	7.55
200-Day Moving Average	7.43
Relative Strength Index (RSI)	41.53
Average Volume (20 Days)	1,294,495

Income Statement

In the last 12 months, Emergent BioSolutions had revenue of 1.01B and earned -190.6M in profits. Earnings per share was -3.6.

Revenue	1.01B
Gross Profit	305.2M
Operating Income	-108.7M
Net Income	-190.6M
EBITDA	36.9M
EBIT	-71.9M
Earnings Per Share (EPS)	-3.6

Full Income Statement

Balance Sheet

The company has 99.5M in cash and 663.7M in debt, giving a net cash position of -564.2M.

Cash & Cash Equivalents	99.5M
Total Debt	663.7M
Net Cash	-564.2M
Retained Earnings	-212.4M
Total Assets	1.42B
Working Capital	592.4M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 58.7M and capital expenditures -22.9M, giving a free cash flow of 35.8M.

Operating Cash Flow	58.7M
Capital Expenditures	-22.9M
Free Cash Flow	35.8M
FCF Per Share	0.68

Full Cash Flow Statement

Margins

Gross margin is 30.11%, with operating and profit margins of -10.72% and -18.8%.

Gross Margin	30.11%
Operating Margin	-10.72%
Pretax Margin	-14.1%
Profit Margin	-18.8%
EBITDA Margin	3.64%
EBIT Margin	-10.72%
FCF Margin	3.53%

Dividends & Yields

EBS does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Payout Ratio	n/a
Earnings Yield	n/a
FCF Yield	n/a

Dividend Details

Analyst Forecast

The average price target for EBS is $15, which is 97.6% higher than the current price. The consensus rating is "Buy".

Price Target	$15
Price Target Difference	97.6%
Analyst Consensus	Buy
Analyst Count	3

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Scores

Altman Z-Score	1.82
Piotroski F-Score	6